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Abstract:  Merkel  cell  carcinoma  (MCC)  is  an  aggressive  cutaneous  neuroendocrine 
malignancy that is associated with a poor prognosis. The pathogenesis of MCC is not well 
understood, and despite a recent plethora of mutational analyses, we have yet to find a set 
of signature mutations implicated in the majority of cases. Mutations, including TP53, 
Retinoblastoma  and  PIK3CA,  have  been  documented  in  subsets  of  patients.  Other 
mechanisms are also likely at play, including infection with the Merkel cell polyomavirus 
in a subset of patients, dysregulated immune surveillance, epigenetic alterations, aberrant 
protein  expression,  posttranslational  modifications  and  microRNAs.  In  this  review,  we 
summarize what is known about MCC genetic mutations and chromosomal abnormalities, 
and their clinical significance. We also examine aberrant protein function and microRNA 
expression,  and  discuss  the  therapeutic  and  prognostic  implications  of  these  findings. 
Multiple clinical trials designed to selectively target overexpressed oncogenes in MCC are 
currently  underway,  though  most  are  still  in  early  phases.  As  we  accumulate  more 
molecular data on MCC, we will be better able to understand its pathogenic mechanisms, 
develop  libraries  of  targeted  therapies,  and  define  molecular  prognostic  signatures  to 
enhance our clinicopathologic knowledge. 
Keywords: merkel cell carcinoma; merkel cell polyomavirus; tumor suppressor; oncogene; 
prognostic algorithm; mutational analysis 
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1. Introduction 
Merkel Cell Carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine tumor. MCC is 
most often found in elderly Caucasians approximately 60–80 years old, with an annual incidence in the 
United States of approximately three cases per million persons per year, though this number has nearly 
tripled in the last 20 years with an aging populace, increased UV exposure and greater frequency of 
immunosuppression in the population [1]. MCC can be up to 13 times more frequent in immunosuppressed 
patient  populations  including  those  with  HIV,  organ  transplants  and  certain  hematologic  cancers 
including  multiple  myeloma,  non-Hodgkin’s  lymphoma  and  chronic  lymphocytic  leukemia  [2,3]. 
Although  the  relationship  between  immunosuppression  and  MCC  is  not  entirely  understood,  the 
discovery of the Merkel cell polyomavirus (MCPyV) infection in up to 80% of cases offers a potential 
mechanism  for  malignant  transformation,  and  may  provide  more  insight  in  this  regard  [4].  The 
mechanisms  of  oncogenesis  underlying  MCPyV-negative  MCC  are  less  well  understood,  but  are 
thought  to  involve  somatic  mutations  in  tumor  suppressors  including  RB1  and  TP53,  as  well 
epigenetic alterations resulting in aberrant expression and activity of oncogenes [5,6]. The extent of 
disease at presentation is a strong predictor of survival, ranging from a 70% 10-year-survival rate in 
patients with isolated local disease, to 20% or less in patients with distant spread [7]. Male sex, tumor 
size, clinical nodal status, metastatic dissemination, lymphovascular invasion, high mitotic index and 
small cell morphology are associated with poor prognosis [8,9]. 
MCC is most frequently found on the head and neck, followed by the upper extremities, lower 
extremities and trunk. Less than one percent of cases are diagnosed in the parotid and submandibular 
glands, nasal cavity, and lymph nodes. Tumors present as firm, flesh-colored (often with red or blue 
hues), painless nodules that are fast growing and tend to metastasize early to lymph nodes and other 
distant organs. Histopathologically, hematoxylin and eosin staining of MCC presents as round blue 
tumor cells, indicative of large basophilic nuclei with minimal cytoplasm, located in the dermis or 
subcutaneous tissue. They may have a trabecular pattern, scant eosinophilic cytoplasmic rims, multiple 
nucleoli and paranuclear staining of cytokeratin-20 (CK-20) in a dot-like pattern. Normal merkel cells 
are located within the stratum basale and rete ridges of epidermis, as well as in mucosa [10,11]. They 
are of ectodermal origin and function in light touch with slow adapting somatosensory afferent fibers. 
There has been limited debate that MCC may not be derived from merkel cells, but rather pluripotent 
stems cells within the skin [12]. 
MCC has historically been difficult to study and treat due to limited epidemiologic data, variable 
response to treatment and outcomes, and lack of associated genetic mutations for targeted therapy. 
Approximately half of the available articles on MCC have been published within the last five years, of 
which few are prospective randomized clinical trials. Although consensus guidelines for management 
of MCC exist, there are still unanswered fundamental clinical questions regarding the best use of 
surgery, chemotherapy and radiation for this condition. 
2. The Role of Mutational Analysis in MCC 
MCC  response  to  treatment  modalities  and  prognosis  is  variable,  and  clinical  and  histologic 
characteristics have limited utility to predict outcome. Underlying the perplexing natural history of Cancers 2014, 6  2118 
 
 
MCC are unique differences in chromosomal abnormalities, genetic mutations, expression profiles and 
epigenetic  controls  of  individual  tumors  that  are  still  poorly  understood.  Recently,  Merkel  cell 
polyomavirus  (MCPyV)  has  been  found  in  up  to  80%  of  MCCs  in  most  reported  series  and  is 
associated with improved outcome compared to virus negative tumors [13]. Better understanding of 
MCC  at  the  molecular  level  will  provide  much  needed  insight  regarding  prognosis,  prediction  of 
response to aggressive surgical excision and chemoradiation, and the development of targeted therapy. 
3. Merkel Cell Polyomavirus 
A key distinction in the mutational analysis of MCC is MCPyV status. Discovered in 2008, this  
is one of the 13 known polyomaviruses that naturally infect humans, though it is the only human 
polyomavirus thought to be involved in tumorigenesis [13]. Up to 60%–80% of the normal population 
will test positive for MCPyV infection, whereas the incidence of infection among MCC patients is 
approximately 80%–90% [14]. Among those infected, anti-VP1 antigen titer is significantly higher  
in MCC patients compared to the normal population [15]. It is not understood why the infection rate or 
antigen  titer  are  higher  in  MCC  patients,  or  what  determines  oncogenic  transformation  in  infected 
patients, though immunocompromise likely plays a role. The incidence of MCC is 15-fold higher 
among  immunocompromised  patients,  and  up  to  30-fold  higher  in  patients  with  certain  liquid  
malignancies  [16,17].  However,  it  has  not  been  validated  to  our  knowledge  that  the  incidence  of 
MCPyV positive MCC is higher in the immunocompromised population than in non-immunocompromised 
patients. MCPyV status of tumors is independent of patient age, whereas MCPyV status among the 
normal population is age dependent [18]. 
The  MCPyV  virus  integrates  its  DNA  into  tumor  cells  in  a  clonal  pattern,  preceding  tumor 
proliferation. There are two relevant viral proteins: large T antigen (LT-Ag) and small T antigen (ST-Ag), 
which have been implicated in oncogenesis through multiple mechanisms. ST-Ag contains an N-terminal 
J  domain  similar  to  LT-Ag,  but  is  otherwise  structurally  unique.  ST-Ag  was  shown  to  inhibit 
proteasomal degradation of LT-Ag and other SCF(bw37) ubiquitin ligase targets, including c-Myc and 
cyclin E, contributing to oncogenesis [19]. ST-Ag has also been found to transform rodent fibroblasts 
via preservation of hyperphosphorylation of 4E-BP1 at S65 resulting in dysregulated cap-dependent 
translation that was resistant to mTORC1 and two inhibitors [20]. 4E-BP1 functions via inhibition of 
eukaryotic translation initiation factor 4E (eIF4E), which is a limiting component of the multisubunit 
complex  that  recruits  40S  ribosomal  subunits  to  the  5'  end  of  mRNAs  for  translation  initiation. 
Knockdown of ST-Ag alone results in growth arrest of MCC cell lines [21]. 
LT-Ag has four putative regions: an N-terminal J-domain, RB1 and DNA binding motifs, and a  
C-terminal  helicase  domain.  The  viral  genomes  recovered  from  MCC  tissue  contain  mutations 
affecting the helicase and DNA binding regions that selectively inhibit LT-Ag ability to support viral 
replication, thereby preventing lytic viral replication that could be lethal to a cancer cell, while still 
maintaining its Rb-binding capacity and cell cycle dysregulating function. The helicase region has 
been shown to promote growth inhibitory functions, likely through induction of DNA damage response 
kinases,  which  may  partly  explain  why  signature  truncation  of  this  region  is  found  in  MCC  [22]. 
Perhaps, the most frequently documented oncogenic function of LT-Ag is its RB1 binding capacity. 
MCC-derived truncated LT-Ag binds RB1 with high affinity, partially relocalizing the protein to the Cancers 2014, 6  2119 
 
 
cytoplasm and suppressing its anti-neoplastic function [23]. This Rb-sequestering function was shown 
to be essential to virus positive MCC proliferation both in in vitro and xenograft models [24]. LT-Ag 
also downregulates expression of TLR9, a key receptor in the host innate immune response that senses 
viral or bacterial dsDNA, thereby liberating infected cells from host immune surveillance. LT-Ag 
achieves  this  affect  via  inhibition  of  C/EPB  binding  at  the  TLR9  promoter  [25].  Unlike  other 
polyomaviruses, full length and truncated MCPyV lack TP53-binding capacity [26]. Most MCCs are 
TP53 wild type and increased TP53 expression is associated with worse prognosis, therefore large and 
small T antigens may affect TP53 function indirectly. 
MCPyV positive tumors are more commonly found in females and are associated with lower stage 
and  better  prognosis,  including  longer  overall  and  disease  free  survival  [4,27–29].  Histologically, 
MCPyV positive tumors have been found to have less nuclear polymorphism and cytoplasmic content, 
consistent with their less sinister course. A higher viral copy number per tumor cell is associated with 
improved survival in complete remission [4]. The association between viral infection and prognosis is 
poorly  understood,  though  may  in  part  be  related  to  immune  response.  The  presence  of  tumor 
infiltrating  cytotoxic  T  cells  (CD8+)  is  independently  associated  with  improved  prognosis,  and 
MCPyV positive tumors have greater numbers of intra- and peritumoral CD3+ and CD8+ T cells [30,31]. 
As expected, on transcriptome analysis, virus positive tumors transcribe significantly more immune 
response  genes  [18].  Alternatively,  it  may  be  that  virus-negative  tumors  have  more  frequent  and 
aggressive somatic mutations. Though there is limited data to support this hypothesis, it has been 
shown that deletion of RB1 and mutations in TP53 are more common in virus negative MCCs [32]. 
Targeted immunotherapy towards T cell antigens and their downstream targets may be promising 
for virus positive tumors. Although up to 80% of the general population will harbor antibodies to 
MCPyV capsid proteins, titers are significantly higher in MCC patients, who also uniquely generate 
antibodies to T antigens. Anti-T antigen titer may be used as a biomarker for disease regression or 
recurrence in a subset of patients. Monoclonal antibodies, vaccines and adoptive cellular approaches 
targeting T antigens and other MCC-specific tumor antigens are being studied as potential therapeutic 
modalities [33]. 
4. Mutations in Tyrosine Kinase Signaling: KIT, PDGFRA, PIK3CA, AKT and PTEN 
PDGFRA and KIT (CD117) are transmembrane receptor tyrosine kinases associated with certain 
cancers including melanoma and acute myeloid leukemia, and activating mutations in both genes have 
been associated with tumorigenesis [34]. MCCs have been found to express both proteins, warranting 
investigation as therapeutic targets [35]. 
Andea et al. evaluated KIT expression in 30 MCC tumors, which was elevated in 67% of cases and 
was associated with a trend towards worse prognosis. Point mutations were found in exons 17 and 18, 
and introns 16 and 17, though no activating mutations were identified [36]. In a similar study, 23 cases 
of  MCC  were  evaluated  for  KIT  and  PDGFRA  expression  and  mutational  status.  65%  of  tumors 
expressed  CD117  and  95%  expressed  PDGFRA.  In  12  of  18  samples,  a  single  nucleotide 
polymorphism (SNP) in KIT exon 11 resulted in an E583K amino acid change, which has previously 
been described as an inactivating mutation in piebaldism, and is unlikely related to tumorigenesis. A 
SNP with silent effect in exon 18 of PDGFRA was found in eight of 18 samples [37]. Kartha et al. Cancers 2014, 6  2120 
 
 
evaluated 14 primary and 18 metastatic MCC tumors for KIT and PDGFRA expression and mutation. 
KIT  and  co-expression of  its  ligand,  SCF,  was  found  in  16%  of  cases,  whereas  co-expression  of 
PDGFA and PDGFRA was observed in 81% of cases. Silent mutations were observed in exon 17 of 
KIT and exons 10, 12 and 18 of PDGFRA, but activating mutations were not found [38]. Based on 
these findings, activating mutations in KIT and PDGFRA receptor tyrosine kinases are unlikely drivers 
of MCC tumorigenesis. Although these proteins may play a role in MCC cellular proliferation and 
survival, the mechanism underlying their aberrant expression and activity is poorly understood. 
Nardi et al. sequenced select mutational hotspots of 60 MCC tumors and found three (5%) TTP53 
point mutations and six (10%) PIK3CA activating point mutations [39]. PIK3CA has been implicated 
in multiple cancers including: liver (36%), breast (26%), colon (25%), urothelial (13%), ovarian (9%), 
gastric (7%), brain (6%), and lung cancer (2%) as well as leukaemia (1%) [40,41]. It serves as an 
intracellular tyrosine kinase that activates AKT downstream to stimulate cell cycle progression via 
mTOR,  cellular  proliferation  via  NF-κb,  and  inhibition  of  apoptosis  via  deactivation  of  tumor 
suppressors including TP53, p21, p27 and GSK3b. Five of the six PIK3CA mutations observed were 
within the helical domain of the p110a subunit, which is mutated in a wide variety of skin cancers [42]. 
These mutations were exclusively found in men, and associated tumors included a mix of primary and 
recurrent disease, had a normal distribution pattern, were significantly larger in size (>2 cm) with 
worse stage, had more necrosis and pleomorphic spindle cell features, and all were MCPyV negative 
except for one case. However, the authors were unable to correlate these findings to worse prognosis, 
likely  due  to  limited  power.  They  tested  multiple  PIK3CA  inhibitors  and  were  able  to  inhibit 
phosphorylation and activation of AKT in multiple MCC cell lines and induce apoptosis in one line 
with both ZST474, a specific phosphoinositide 3-kinase (PI3K) inhibitor, and NVP-BEZ235, a dual 
PI3K/mTOR inhibitor. Although no mutations were observed in the AKT gene, it was shown that a 
subset of MCC samples display high AKT activity in the setting of wild type PIK3CA, suggesting 
upstream  activation  either  through  an  unknown  oncogene  or  disinhibition  from  mutated  tumor 
suppressor, specifically PTEN [39]. 
Hafner et al. also evaluated the PIK3CA pathway in MCC and found 2/46 (4%) MCC had PIK3CA 
mutations  and  none  in  AKT.  However,  activating  phosphorylation  of  AKT  was  found  in  88%  of  
MCCs, which was uncorrelated with MCPyV status, and cells were sensitive to the PIK3CA inhibitor  
LY-294002  [43].  Based  on  these  data,  upstream  or  epigenetic  aberrations  are  likely  driving  the 
pathway given the lack of intrinsic mutations. 
PTEN (phosphatase and tensin homologue) is a tumor suppressor implicated in many cancer types, 
which  functions  by  inactivating  AKT  via  dephosphorylation.  Chromosomal  analysis  of  21  MCC 
samples showed hemizygous mutations in nine (43%) samples of the10q23 region of Ch10, where 
PTEN is located. However, homozygous deletions or point mutations of the remaining allele were 
quite rare, suggesting alternate mechanisms of PTEN inactivation or the involvement of other tumor 
suppressors in MCC [44]. 
More work is needed to elucidate the mechanisms of constitutive PIK3CA/AKT activation in MCC 
given the relative paucity of pathway mutations, and to better characterize the function of these genetic 
aberrations  in  oncogenesis  and  prognosis.  Tyrosine  kinase  inhibitors  may  still  play  an  important 
chemotherapeutic role, and there are currently multiple ongoing clinical trials (Table 1). Most are still Cancers 2014, 6  2121 
 
 
in early phases and incomplete. The only completed to date trial is a phase II study of imatinib that 
showed no benefit in advanced MCC patients [45]. 
Table 1. Clinical trials for tyrosine kinase inhibitors in Merkel Cell Carcinoma (MCC). 
Generic 
Name 
Trade/Co
de Name 
Mechanism of 
Action 
Trials in other Cancers 
MCC 
Trial 
Phase 
Trial Status  Additional 
Pazopanib 
[46] 
Votrient 
Multi-targeted 
tyrosine kinase 
inhibitor 
Renal cell, soft tissue sarcoma, 
lung, ovarian, breast, prostate, 
neuroendocrine, thyroid, 
cervical, cholangiocarcinoma, 
germ cell, urothelial and 
fallopian tube cancers 
Phase 2  Recruiting   
Cabozantinib 
[47] 
Cometriq 
Targeted inhibitor 
of c-Met and 
VEGFR2 
Thyroid, melanoma, breast, 
pancreatic, prostate, brain, 
bladder and ovarian cancers 
Phase 2  Recruiting   
Nelfinavir 
[48] 
Viracept   
Pancreatic, brain, cervical, 
head and neck, rectal, soft 
tissue sarcoma, and non-small 
cell lung cancers 
Phase 1  Unknown   
Cixutumumab 
[49] 
IMC-A12 
Monoclonal 
antibody targeting 
IGF-1R 
Esophageal, soft tissue 
sarcoma, lung, liver, prostate, 
melanoma, breast, colorectal 
and thymoma cancers 
Phase 1 
Ongoing, not 
recruiting 
In combination 
with 
Everolimus 
Everolimus 
[49,50] 
Afinitor  Inhibitor of mTOR 
Breast, brain, pancreatic, liver, 
colorectal, lung, head and 
neck, fallopian tube, gastric, 
thyroid, prostate, endometrial, 
renal cell, and cervical cancers 
Phase 1 *, 
Phase 1 ** 
Ongoing, not 
recruiting *, 
Ongoing, not 
recruiting ** 
Separate trials 
in combination 
with 
Cixutumumab 
and Vatalanib 
Vatalanib 
[50] 
PTK787 
Inhibitor of  
VEGF-1 and 2, 
PDGFRβ and KIT 
Hematologic, GIST, 
pancreatic, brain, colorectal, 
prostate, breast, melanoma, 
lung and mesothelioma cancers 
Phase 1 
Ongoing,  
not recruiting 
In combination 
with 
Everolimus 
Temsirolimus 
[51] 
Torisel  Inhibitor of mTOR 
Thyroid, prostate, breast, liver, 
head and neck, endometrial, 
ovarian, neuroendocrine, 
gastric, cervical, pancreatic, 
renal, lung, colorectal, 
esophageal and brain cancers 
Phase 1 
Ongoing,  
not recruiting 
In combination 
with 
Vinorelbine 
Imatinib 
[52] 
Gleevec 
Inhibitor of  
BCR-ABL 
Hematologic, GIST, ovarian, 
breast, head and neck, lung, 
colorectal, thyroid, testicular, 
prostate, renal, gastric, brain, 
melanoma, pancreatic and 
sarcoma cancers 
Phase 2  Completed 
No  
observed 
benefit 
VEGFR2, Vascular Endothelial Growth Factor Receptor 2; IGF-R1, Insulin Growth Factor-1 Receptor; mTOR, Mammalian Target of 
Rapamycin; VEGF-1/2, Vascular Endothelial Growth Factor 1/2; PDGFRβ, Platelet Derived Growth Factor Receptor Beta; BCR-ABL, 
Breakpoint Cluster Region-Abelson Murine Leukemia gene. * Everolimus and Cixutumumab combination therapy trial; ** Everolimus 
and Vatalanib combination therapy trial. 
   Cancers 2014, 6  2122 
 
 
5. Mutations in Tumor Suppressors: TP53 and RB1 
Mutations in the TP53 tumor suppressor have rarely been found in MCC, ranging from 0%–28% in 
most studies, the majority of which represent SNPs or silent mutations with unknown or no clinical 
significance  [53–56].  Of  note,  Waltari  et  al.  2011  analyzed  87  MCC  tumors  and  found  no  TP53 
mutations, though TP53 protein expression was detected in 22.8% of samples, and was associated with 
MCPyV negative status and worse disease specific (p = 0.021) and overall survival (p = 0.46) [55]. 
Lassacher  et  al.  evaluated  21  MCC  tumors  for  mutations  in  tumor  suppressors  and  oncogenes 
commonly seen in skin cancers. They found  three mutations in TP53 (14%) and one mutation in 
p16INK4a, though no mutations in Ha-Ras, N-Ras, KIT or p14ARF. However, inactivating p14ARF 
promoter methylation was present in eight of 19 analyzable samples (42%), suggesting that epigenetic 
tumor  suppressor  silencing  may  play  a  role  in  MCC  oncogenesis  [56].  In  contrast,  the  tumor 
suppressor  p73,  a  structural  homologue  of  TP53,  was  mutated  in  four  of  15  MCC  samples,  with 
unclear significance [57]. Based on these studies, TP53 inactivating mutations unlikely contribute to 
MCC oncogenesis. 
Prior work has validated that TP53 expression is a marker for poor prognosis in multiple tumor  
types [58]. Normal functioning TP53 is typically undetectable at the protein level due to its short  
half-life and rapid turnover. Although in certain cases missense mutations in TP53 can prevent its 
degradation and tumor suppressive function, the majority of MCC samples studied to date have had 
wild type TP53, and therefore other mechanisms are likely at play. In this regard, the mouse double minute 
2 homolog (MDM2) protein may be of therapeutic significance. This protein forms a complex with 
TP53 in the cytoplasm, preventing the tumor suppressor from binding its responsive element and initiating 
anti-proliferative and DNA repair mechanisms. Due to this sequestration, TP53 accumulates and remains 
nonfunctional [59]. This process has been described in sarcoma, where it was shown that MDM2 was 
amplified in one third of 47 samples, and was specifically associated with detectable expression of 
TP53 [60]. Houben et al. looking specifically at MCC, studied whether T antigens contributed to TP53 
stabilization and found that viral knockdown did not lead to resumed TP53 function. However, they 
found that inhibition of MDM2 by the compound Nutlin-3a did induce TP53 transcriptional activation, 
resulting in tumor cell apoptosis in five of seven lines with wild type TP53 [61]. 
Retinoblastoma (Rb) inactivation is thought to play an important role in the pathogenesis of MCC.  
In MCPyV-positive cancers, sustained tumor growth is contingent on the presence of a functional large 
T antigen with intact RB1 binding domain to sequester and inactivate the tumor suppressor, which may 
serve as an important therapeutic target for the subset of MCPyV-positive cancers [23,24]. RB1 is also 
frequently downregulated in virus negative tumors, though the mechanisms of inactivation are still 
under investigation. Leonard et al. evaluated 24 MCC samples for hemizygous deletions, and found 
that 75% of tumors contained deletions in chromosome 13 near the RB1 locus [62]. A separate study 
showed that virus negative tumors had increased genomic instability compared to virus positive MCCs 
with  higher  rates  of  deletion  in  the  RB1  locus  that  correlated  with  decreased  RB1  detection  by 
immunohistochemistry.  Additionally,  they  found  RB1  promoter  hypermethylation  in  all  tumor 
samples, irrespective of MCPyV status and RB1 expression [5]. In addition to chromosomal deletion, a 
higher frequency  of nonsense truncating mutations in  the RB1  gene has  been shown in  MCPyV-
negative tumors [63]. Cancers 2014, 6  2123 
 
 
6. Chromosomal Abnormalities 
Chromosomal aberrations can potentially provide insights into the pathogenesis of MCC, reveal 
specific gene targets, and serve as a diagnostic resource. Initial forays into chromosomal analysis in 
MCC utilized comparative genomic hybridization (CGH) to define copy number abnormalities, but 
lacked the resolution to isolate specific gene candidates. Frequently amplified regions have been found 
on chromosomes 1, 5, 6, 8 and 20, and frequent losses on chromosomes 13 and 4 (Table 2) [6,64,65]. 
Chromosomal alterations are associated with larger tumors at higher risk for metastatic dissemination [64]. 
However, most studies lack evidence for high-level amplifications [66]. The advent of microarrays has 
greatly improved the resolution of hybridization, and can provide copy number information at the 
single  gene  level.  Using  array-CGH  technology,  Paulson  et  al.  evaluated  23  MCC  samples,  and 
similarly found that tumors frequently carried additional copy regions of chromosomes 1, 3q, 5p, and 6 
and lost chromosomes 3p, 4, 5q, 7, 10 and 1. MCPyV positive tumors had fewer genetic alterations. 
Three chromosomal regions were of interest, including a deletion of 5q12–21 found in 26% of tumors, 
a deletion of 13q14–21 also found in 26% of tumors that contains the RB1 tumor suppressor, and 
amplification at 1p34 present in 39%, which contains the L-Myc (MYCL1) oncogene [67]. 
Table 2. Chromosomal abnormalities in MCC. 
Chromosome  Deletion/Amplification 
1 
Amplification of 1p34 in 9/23 (39%) tumor samples, contains L-Myc [67]. 
Deletion of 1p32–33, 1p35 and 1p36 in 16/24 (73%) of MCC tumor samples, 1p36.33 contains p73 tumor 
suppressor [57]. 
Amplification of 1q11q31 in 32% of 19 primary MCC tumors analyzed, high-level amplification of 
1q22q24 in 5% of samples [64]. 
Deletion of 1p35–36 in 7/10 (70%) of MCC samples [68]. 
Deletion of 1p arm in 3/3 (100%) of MCC samples [69]. 
3 
34 tumors samples from 24 patients revealed frequent loss for chromosomes 3p (46%), 5q (21%),  
8p (21%), 10 (33%), 11q (17%), 13q (33%) and 17p (25%), and gains were seen for chromosomes 1 
(63%), 3q (33%), 5p (38%), 8q (38%), 19 (63%), and X (41%) [70]. 
18/25 (69%) of tumor samples demonstrated 3p deletions ranging from 3p13–p21.1 [71]. 
5 
Amplification of 5p in 32% and high-level amplification of 5p in 5% of 19 MCC samples [64]. 
Deletion of 5q12–21 in 26% cases of 23 tumor samples [67]. 
6 
Amplification of 6p in 8/19 cases (42%), most common 6pterqter [64]. 
Trisomy in 8/17 cases (47%) [72]. 
Trisomy in 2/4 lymph nodes samples and 6/10 primary tumor samples [73]. 
Trisomy documented in a single patient case report of disease recurrence [74]. 
7 
Case report document deletion of the long arm with break point at 7q31, as well as trisomy of 
chromosomes 6 and 11 [75]. 
8 
Trisomy documented in a single patient case report of disease recurrence [74]. 
Amplification of 8q21–q22 and loss of 4p15-pter [6]. 
10  Deletion of 10q23 in 9/21 (43%) cases, containing the PTEN locus [44]. 
13 
Deletion of 13q13q31 (21%), 4q (16%), and 16q (11%) in 19 MCC samples [64]. 
Deletion of 13q14–21 in 26% of 23 tumor samples [67]. 
Deletion of 13p in 18/24 75% cases, most commonly deleted region was mapped close to the RB1 
susceptibility gene 13p14.3 [62]. 
22  Case report documenting deletion of 22p in 100% and 22q in 85% of MCC cells from a patient sample [76]. 
PTEN, Phosphatase and tensin homolog. Cancers 2014, 6  2124 
 
 
7. MicroRNAs 
MicroRNAs (miRNAs) are non-coding RNA sequences approximately 18–22 bases in length that 
silence translation of complementary messenger RNA transcripts, thereby regulating post-transcriptional 
gene expression. Discovered within the last 20 years, miRNAs have been shown to play critical roles 
in multiple biologic processes, and they are often deregulated in cancers. Certain miRNAs have been 
directly linked to oncogenesis, and provide potential diagnostic, therapeutic and prognostic value. 
Xie et al. evaluated miRNA expression patterns of MCC, and found distinct expression profiles 
based on MCPyV status. Specifically, miR-203, miR-30a-3p, miR-769-5p, miR-34a, miR-30a-5p, and 
miR-375 were significantly different between the two groups. They also identified multiple miRNAs 
associated with decreased survival and metastases, including: miR-150, mi-146, miR-630, miR-483-
5p, and miR-142-3p. However, only miR-150 was statistically significant, and may potentially serve as 
a useful prognostic marker [77]. 
MiR-203  suppresses  multiple  targets  involved  in  oncogenesis,  and  is  downregulated  in  certain 
cancers  [78–81].  In  MCC,  miR-203  has  been  shown  to  suppress  expression  of  survivin,  a  highly 
conserved member of the inhibitor of apoptosis (IAP) family that is overexpressed and contributes to 
tumorigenesis [82]. Xie et al. showed that miR-203 overexpression resulted in decreased transcript and 
protein detection of the survivin gene, which was associated with increased cell cycle arrest, though in 
MCPyV negative cells only. In virus positive tumors, LT-Ag is thought to inhibit survivin expression 
via sequestration of the RB1 tumor suppressor, and RNA silencing of LT-Ag was able to restore 
susceptibility  to  miR-203  overexpression.  Thus,  survivin  expression  appears  to  be  differentially 
regulated by miR-203 and LT-Ag in virus negative and positive MCCs, respectively [77]. Recently, 
YM-155, a direct survivin inhibitor, has been shown be cytotoxic to MCPyV positive MCC cells at 
nanomolar  concentrations  in  mouse  xenografts,  improving  survival,  and  therefore  may  serve  as  a 
potential therapeutic target for MCC [83]. In MCPyV negative cells, miR-203 delivery may provide an 
alternative novel therapeutic target. 
Ning et al. evaluated the miRNome in MCC and found significant upregulation of miR-502-3p,  
miR-9, miR-7, miR-340, miR-182, miR-190b, miR-873, and miR-183 relative to non-MCC cutaneous 
tumors and normal skin controls. They found downregulation of miR-3170, miR-125b, and miR-374c [84]. 
miR-125b  downregulation  in  breast  and  hepatocellular  carcinomas  is  associated with  disinhibition  
of  cellular  proliferation  and  anti-apoptotic  programs,  and  overexpression  may  restore  regulatory 
mechanisms [85]. In contrast, in melanoma, miR-182 expression is associated with tumor proliferation 
and invasion, likely via suppression of the FOXO3 tumor suppressor [86]. The role of under- and 
overexpression of miRNAs in MCC is still poorly understood, though may provide a novel library of 
therapeutic targets. 
8. Negative Mutational Findings 
MCC pathogenesis has been difficult to characterize given the abundance of negative mutational 
studies (Table 3). To date, several highlights have been reported: mutations in TP53 ranging from 
approximately 5%–28% in most series, variable deletion of the RB1 locus, and more recently, a novel 
study reporting a 10% frequency of mutation of PIK3CA in 60 MCC samples [5,39,56]. Aberrant Cancers 2014, 6  2125 
 
 
expression and activity of both tumor suppressors and oncogenes have been frequently documented in 
MCC, yet the paucity of associated mutations suggests that this cancer may lack a defining profile 
such  as  the  BCR-ABL  mutation  in  chronic  myelogenous  leukemia.  Rather,  oncogenesis  is  likely 
predicated  on  poorly  understood  dysregulated  processes  including  epigenetic  programs,  post-
transcriptional gene regulation, and post-translational modifications. 
Table 3. Mutational analyses with negative findings in MCC. 
Negative Study  Description 
p14ARF, p16INK4,  
H-Ras, K-Ras, N-Ras, 
KIT 
1/20 (5%) p16INK4 mutations, no mutations in any of the other genes; 
hypermethylation of p14ARF suggesting downregulation of the tumor suppressor [56]. 
p73 and TP53 
Missense mutation in p73 of unclear significance in 15 samples. One TP53  
nonsense mutation [57]. 
PTEN 
Hemizygous mutations in 9/21 MCC samples, though remaining allele unmutated. 
Epigenetic silencing of remaining allele is possible though yet to be shown [44]. 
PDGFA  Expression detected in 25/31 (81%) of cases, though no activating mutations [38]. 
c-KIT  Expressed in 8/9 (89%) of cases, though no activating mutations [87]. 
Wnt 
Elevated β-catenin in only 1/12 (8%) cases, no mutations. Similarly no mutations 
in APC [88]. Lill et al. 2013 found no increased expression of β-catenin or cyclin 
D in MCC samples [89]. 
BRAF 
No mutations in exon 15 (commonly mutated region in melanoma) in 15 samples 
tested [90]. No. V600E mutations, which is found in 43% of melanomas, in 46 MCC 
samples [91]. 
MAPK Pathway 
High expression of Raf Kinase Inhibitor Protein (RKIP), which deactivates the 
pathway. Expression though lack of phosphorylated activation of ERK in 42/44 
(95%) cases, representing lack of activation [91]. 
ALK 
Expressed in 26/32 (81%) of MCC samples, no rearrangement or other cytogenetic 
abnormality of the locus identified [92]. 
HRAS, KRAS, NRAS, 
BRAF, cKIT 
No mutations in exons 1 and 2 of all genes studied in 6 MCC cell lines [6]. 
RON and MSP 
No mutations, though transcription of both genes in 9/14 MCC samples and  
no controls [93]. 
Notch-1 
Tumor suppressor downregulated in lung and gastrointestinal neuroendocrine 
tumors, found to be expressed in 30/31 (97%) of MCC samples, thus unlikely to 
play a role in oncogenesis. Mutational status no evaluated [94]. 
APC, BRAF, β-catenin, 
EGFR, FLT3, JAK2, 
cKIT, KRas, NRas, 
Notch-1, PTEN 
No mutations in hotspots of these genes in 60 MCC samples [39]. 
p14ARF,  p14  Alternate  Reading  Frame;  Ras,  Rat  Sarcoma;  PTEN,  Phosphatase  and  tensin  homolog; 
PDGFA,  Platelet  Derived  Growth  Factor  Alpha;  Wnt,  Wingless-related  integration  site;  BRAF,  Rapidly 
Accelerated Sarcoma B; MAPK, Mitogen Activated Protein Kinase; ALK, Anaplastic Lymphoma Kinase; 
RON, Recepteur d’Origine Nantais; MSP, Macrophage Stimulating Protein; APC, Adenomatous Polyposis 
Coli; EGFR, Epidermal Growth Factor Receptor; FLT3, FMS-like Tyrosine Kinase 3; JAK2, Janus Kinase 2. 
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9. Molecular Prognostic Algorithm 
Although MCC prognosis is on average quite poor, there is considerable range in survival, yet we 
have limited capacity to predict outcome. Most studies on survival in MCC have historically focused 
on clinicopathologic features including tumor size and location, histologic features such as nuclear 
atypia and lymphovascular invasion, and metastases to lymph nodes and distant sites. However, with 
advances in molecular diagnostics, characterization of MCC signatures will provide better accuracy for 
predicting prognosis in the individual patient. There are already multiple studies correlating expression 
of  one  or  several  genes  with  prognosis  in  MCC,  typically  via  protein  expression  using 
immunohistochemistry (IHC), and the information from these resources could be synthesized to create 
a prognostic molecular profile (Table 4). MCPyV status may also be an important bifurcation, as virus 
negative tumors have been shown to have worse prognosis in some series (Figure 1) [32,39]. 
Table 4. Markers associated with prognosis in MCC. 
Expressed Marker  Association with MCC Prognosis 
MCPyV 
Associated with LT-Ag and RB1expression and absence of TP53 expression, and was 
associated with improved disease specific and overall survival (p < 0.01) on univariate  
analysis [95]. Polyomavirus-positive Merkel cell carcinomas showed better prognosis with one 
spontaneous regression case and significantly higher expression of retinoblastoma protein  
(p = 0.0003) and less TP53 expression (p = 0.0005) compared to MCPyV negative MCC [32]. 
Intratumoral CD8  Independent predictor of survival on multivariate analysis (p = 0.01) [31]. 
Anti-LTAg 
Associated with MCPyV infection, titer level correlated with disease progression. Rise in T-Ag 
titer preceded tumor recurrence, may have biomarker potential [96]. 
Anti-VP1 
High anti-VP1 titers associated with improved progression free survival in MCC patients  
(p = 0.003) [97]. 
p63 
p63 is expressed in more advanced disease, though its role as a prognostic tool is  
undetermined. In two different series, p63 expression was significantly associated with 
decreased survival [98,99]. However, a separate study of 95 patients found no correlation 
between p63 and prognosis [100]. 
Ki-67  Ki-67 labeling index exceeding 50% correlated with poor prognosis [101]. 
Ep-CAM  Highly expressed in metastasizing MCC [102]. 
Cyclin A, Tenascin-C  Associated with worse prognosis [103]. 
Patched and IHH 
Sonic Hedgehog (SHH) pathway proteins were frequently and intensely over-expressed in the 
MCCs in this study (Sonic hedgehog, 93%; Indian hedgehog, 84%; Patched, 86%; Smoothened, 
79%; Gli-1, 79%; Gli-2, 79%; Gli-3, 86%) compared with control samples. High levels of 
Patched and Indian hedgehog were significantly associated with an increase in patients overall  
(p = 0.015) and recurrence-free survival (p = 0.011), respectively [104]. 
MMP2/7/10, TIMP3, VEGF, P38, 
NF-kappaB, and Synaptophysin 
Expression correlated with metastatic tumor spread [105]. 
PIN1 
Binds and stabilizes TP53, causing cell cycle arrest and growth inhibition. Found to be 
expressed in all 27 MCC samples studied to varying degrees. High expression was significantly 
associated with improved overall survival (50% 5-years survival vs. 14%; p = 0.03) [106]. 
miR-150 
miR-150, mi-146, miR-630, miR-483-5p, and miR-142-3p associated with worse prognosis, 
though only miR-150 reached statistical significance [77]. 
CD34 and Chromogranin  Trend towards favorable prognosis [107]. 
MCPyV,  Merkel  cell;  Rb,  Retinoblastoma;  Ep-CAM,  Epithelial  Cell  Adhesion  Molecule;  IHH,  Indian  Hedgehog;  MMP,  matrix 
metalloproteinase; TIMP3, Tissue Inhibitor of Metalloproteinase 3; VEGF, Vascular Endothelial Growth Factor; PIN1, Peptidyl-prolyl 
cis-trans isomerase 1. Cancers 2014, 6  2127 
 
 
Figure 1. Prognostic algorithm for MCC. 
 
CT, computer tomography; MR, magnetic resonance; MCPyV, Merkel cell polyomavirus; Rb, Retinoblastoma; 
PI3K,  Phosphatidylinositol-4,5-bisphosphate  3-kinase;  PTEN,  PTEN,  Phosphatase  and  tensin  homolog; 
PDGFRA, Platelet Derived Growth Factor Receptor Alpha; Ep-CAM, Epithelial Cell Adhesion Molecule; 
IHH, Indian Hedgehog; MMP, matrix metal oproteinase; TIMP3, Tissue Inhibitor of Metalloproteinase 3; 
VEGF, Vascular Endothelial Growth Factor; PIN1, Peptidyl-prolyl cis-trans isomerase 1. 
10. Conclusions 
Despite a recent plethora of mutational studies in MCC, we have yet to find a disruptive pathway 
that is the driving factor in the majority of cases. Mutations in TP53, Rb, and PIK3CA, found in the 
minority of patients, may provide an avenue for the development of therapeutic targets for certain 
patients. However, as this review suggests, continued searches for gene mutations, which are only one 
facet of cancer pathophysiology, may be of limited value. Many of the oncologic pathways seen in 
other  cancers  have  been  rigorously  evaluated  for  missense  and  nonsense  mutations  in  MCC  with 
disappointingly low yield. It is possible that we have merely been looking at the wrong pathways, and 
defining  mutations  are  waiting  to  be  discovered.  However,  as  many  of  these  studies  have 
serendipitously  found,  although  certain  oncogenes  are  not  mutated,  they  have  abnormally  high 
expression and activity that is likely still of clinical significance. MCC is elusive in that perhaps many 
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of the driving mechanisms of this cancer are imbedded in still poorly understood processes such as 
immune surveillance, epigenetic alterations, aberrant protein expression, posttranslational modifications 
and microRNAs. Going forward, application of functional genomics and proteomics is greatly needed 
to provide the insights necessary to develop effective therapies. 
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